Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with ¹¹¹In-labeled exendin-4.

ABSTRACT: Radiolabeled exendin derivatives are promising for non-invasive quantification of pancreatic beta cell mass (BCM); longitudinal observation of BCM for evaluation of therapeutic effects has not been achieved. The aim of this study is to demonstrate the usefulness of our developing method using [Lys¹²(¹¹¹In-BnDTPA-Ahx)]exendin-4 to detect longitudinal changes in BCM. We performed a longitudinal study with obese type 2 diabetes model (db/db) mice administered canagliflozin, which is reported to preserve BCM. Six-week-old mice were assigned to a canagliflozin-administered group or a control group. Blood glucose levels of the canagliflozin group were significantly lower than those of the control group. Plasma insulin levels, insulin secretion during OGTT and insulin conten

SUBMITTER: Hamamatsu K 

PROVIDER: S-EPMC6893013 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature